0001214659-21-012329.txt : 20211126 0001214659-21-012329.hdr.sgml : 20211126 20211126171520 ACCESSION NUMBER: 0001214659-21-012329 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211123 FILED AS OF DATE: 20211126 DATE AS OF CHANGE: 20211126 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jordan Edward P. CENTRAL INDEX KEY: 0001600814 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35798 FILM NUMBER: 211452255 BUSINESS ADDRESS: STREET 1: C/O AMAG PHARMACEUTICALS, INC. STREET 2: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 6174982850 MAIL ADDRESS: STREET 1: C/O AMAG PHARMACEUTICALS, INC. STREET 2: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER NAME: FORMER CONFORMED NAME: Edward P. Jordan DATE OF NAME CHANGE: 20140221 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HUMANIGEN, INC CENTRAL INDEX KEY: 0001293310 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770557236 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 533 AIRPORT BLVD. STREET 2: SUITE 400 CITY: BURLINGAME STATE: CA ZIP: 94010 BUSINESS PHONE: 650.243.3100 MAIL ADDRESS: STREET 1: 533 AIRPORT BLVD. STREET 2: SUITE 400 CITY: BURLINGAME STATE: CA ZIP: 94010 FORMER COMPANY: FORMER CONFORMED NAME: KALOBIOS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20040609 4 1 marketforms-54401.xml PRIMARY DOCUMENT X0306 4 2021-11-23 0001293310 HUMANIGEN, INC HGEN 0001600814 Jordan Edward P. C/O HUMANIGEN, INC. 533 AIRPORT BOULEVARD, SUITE 400 BURLINGAME CA 94010 false true false false Chief Commercial Officer Stock Option (Right to Buy) 5.93 2021-11-23 4 D false 4966 4.53 D 2021-10-31 2031-09-30 Common Stock 4966 0 D As reported in a Form 8-K filed by Humanigen, Inc. (the "Company") on November 26, 2021, with the approval of the compensation committee of the board of directors of the Company, the reporting person accepted the Company's offer to rescind his participation in the program pursuant to which the reporting person had agreed to receive stock options in lieu of 25% of his base salary for the fourth quarter of 2021, or $22,485. As a result, the stock option granted to the reporting person on September 30, 2021 was cancelled, and the reporting person will receive 100% of his base salary for the fourth quarter of 2021 in cash. The amount shown in column 8 equals the fair value of the option on the grant date of September 30, 2021 as calculated using the Black-Scholes options pricing model. /s/ Timothy E. Morris, Attorney-in-fact 2021-11-26